DE59101397D1 - O-glycosyliertes ifn-alpha. - Google Patents
O-glycosyliertes ifn-alpha.Info
- Publication number
- DE59101397D1 DE59101397D1 DE59101397T DE59101397T DE59101397D1 DE 59101397 D1 DE59101397 D1 DE 59101397D1 DE 59101397 T DE59101397 T DE 59101397T DE 59101397 T DE59101397 T DE 59101397T DE 59101397 D1 DE59101397 D1 DE 59101397D1
- Authority
- DE
- Germany
- Prior art keywords
- ifn alpha
- glycosylated ifn
- glycosylated
- alpha
- objects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE59101397T DE59101397D1 (de) | 1990-07-10 | 1991-07-06 | O-glycosyliertes ifn-alpha. |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904021917 DE4021917A1 (de) | 1990-07-10 | 1990-07-10 | Glykosyliertes ifnalpha |
| DE19904035877 DE4035877A1 (de) | 1990-11-12 | 1990-11-12 | O-glycosyliertes ifn-alfa2 |
| PCT/EP1991/001266 WO1992001055A1 (de) | 1990-07-10 | 1991-07-06 | O-glycosyliertes ifn-alpha |
| DE59101397T DE59101397D1 (de) | 1990-07-10 | 1991-07-06 | O-glycosyliertes ifn-alpha. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE59101397D1 true DE59101397D1 (de) | 1994-05-19 |
Family
ID=25894855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59101397T Expired - Fee Related DE59101397D1 (de) | 1990-07-10 | 1991-07-06 | O-glycosyliertes ifn-alpha. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0538300B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH06502987A (cg-RX-API-DMAC7.html) |
| KR (1) | KR930701601A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE104348T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU650893B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2084514A1 (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ386392A3 (cg-RX-API-DMAC7.html) |
| DE (1) | DE59101397D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0538300T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2063515T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI930058L (cg-RX-API-DMAC7.html) |
| HU (1) | HUT65846A (cg-RX-API-DMAC7.html) |
| NO (1) | NO930059D0 (cg-RX-API-DMAC7.html) |
| PL (1) | PL297610A1 (cg-RX-API-DMAC7.html) |
| SK (1) | SK386392A3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1992001055A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| NZ245771A (en) * | 1992-02-07 | 1994-08-26 | New England Medical Center Inc | Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists |
| US5541071A (en) * | 1992-02-07 | 1996-07-30 | New England Medical Center Hospitals, Inc. | Assay for identifying antagonists of gastrin and CCK-B receptors |
| EP0626448A3 (de) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
| EP0788556A1 (en) | 1994-10-28 | 1997-08-13 | Innogenetics N.V. | New polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms |
| EP0920522B1 (en) * | 1996-08-14 | 2003-10-29 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | A vector for polynucleotide vaccines |
| GB9904695D0 (en) * | 1999-03-01 | 1999-04-21 | Imp Cancer Res Tech | Peptide |
| EP1983055A1 (en) | 2000-04-12 | 2008-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| DK2322229T3 (en) * | 2001-10-10 | 2017-03-27 | Novo Nordisk As | Remodeling and Glycoconjugation of Factor IX |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| BRPI0408358A (pt) | 2003-03-14 | 2006-03-21 | Neose Technologies Inc | polìmeros hidrossolúveis ramificados e seus conjugados |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| ES2560657T3 (es) | 2004-01-08 | 2016-02-22 | Ratiopharm Gmbh | Glicosilación con unión en O de péptidos G-CSF |
| EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
| US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
| JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
| NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| AR078117A1 (es) | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES |
| US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| WO2014102103A2 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Heterologous intron within a signal peptide |
| WO2014102101A1 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
| RU2610173C1 (ru) * | 2016-03-30 | 2017-02-08 | Илья Александрович Марков | Рекомбинантная плазмида pFM-IFN-17, обеспечивающая экспрессию интерферона альфа-2b человека, рекомбинантная плазмида pFM-АР, обеспечивающая экспрессию фермента метионинаминопептидазы E. coli, биплазмидный штамм Escherichia coli FM-IFN-АР (pFM-IFN-17, pFM-АР) - продуцент (Met-) рекомбинантного интерферона альфа-2b человека |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN150740B (cg-RX-API-DMAC7.html) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| EP0085693A1 (en) * | 1981-08-14 | 1983-08-17 | A/S Alfred Benzon | Subjects relating to human inteferon-alpha subtype proteins and corresponding antibodies |
| DE3306060A1 (de) * | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
-
1991
- 1991-07-06 KR KR1019930700049A patent/KR930701601A/ko not_active Withdrawn
- 1991-07-06 EP EP91912306A patent/EP0538300B1/de not_active Expired - Lifetime
- 1991-07-06 AT AT91912306T patent/ATE104348T1/de not_active IP Right Cessation
- 1991-07-06 AU AU82082/91A patent/AU650893B2/en not_active Ceased
- 1991-07-06 WO PCT/EP1991/001266 patent/WO1992001055A1/de not_active Ceased
- 1991-07-06 JP JP3511638A patent/JPH06502987A/ja active Pending
- 1991-07-06 SK SK3863-92A patent/SK386392A3/sk unknown
- 1991-07-06 CA CA002084514A patent/CA2084514A1/en not_active Abandoned
- 1991-07-06 DE DE59101397T patent/DE59101397D1/de not_active Expired - Fee Related
- 1991-07-06 FI FI930058A patent/FI930058L/fi not_active Application Discontinuation
- 1991-07-06 HU HU9300036A patent/HUT65846A/hu unknown
- 1991-07-06 DK DK91912306.7T patent/DK0538300T3/da active
- 1991-07-06 PL PL29761091A patent/PL297610A1/xx unknown
- 1991-07-06 ES ES91912306T patent/ES2063515T3/es not_active Expired - Lifetime
-
1992
- 1992-12-23 CZ CS923863A patent/CZ386392A3/cs unknown
-
1993
- 1993-01-08 NO NO930059A patent/NO930059D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK386392A3 (en) | 1994-08-10 |
| NO930059L (no) | 1993-01-08 |
| CA2084514A1 (en) | 1992-01-11 |
| FI930058A0 (fi) | 1993-01-08 |
| EP0538300A1 (de) | 1993-04-28 |
| FI930058A7 (fi) | 1993-01-08 |
| AU650893B2 (en) | 1994-07-07 |
| HU9300036D0 (en) | 1993-04-28 |
| ATE104348T1 (de) | 1994-04-15 |
| NO930059D0 (no) | 1993-01-08 |
| KR930701601A (ko) | 1993-06-12 |
| ES2063515T3 (es) | 1995-01-01 |
| FI930058L (fi) | 1993-01-08 |
| CZ386392A3 (en) | 1993-08-11 |
| JPH06502987A (ja) | 1994-04-07 |
| AU8208291A (en) | 1992-02-04 |
| DK0538300T3 (da) | 1994-10-10 |
| EP0538300B1 (de) | 1994-04-13 |
| HUT65846A (en) | 1994-07-28 |
| PL297610A1 (cg-RX-API-DMAC7.html) | 1992-07-13 |
| WO1992001055A1 (de) | 1992-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE59101397D1 (de) | O-glycosyliertes ifn-alpha. | |
| PT88385A (pt) | Process for preparing conjugates of citokines with immunoglobulins | |
| ID28003A (id) | Turunan-turunan adamantana | |
| ES2036737T3 (es) | Procedimiento para la obtencion de mezclas farmaceuticas. | |
| NO922005D0 (no) | Farmasoeytiske preparater | |
| DE3787002D1 (de) | Synthetische peptide, die zellulaere immunitaet gegen den aids-virus und dessen proteine erzeugen. | |
| ITRM920237A1 (it) | Perfezionato impiego di medicinali broncodilatatori b2. | |
| DK0540609T3 (da) | Cephalosporiner og homologer, fremstillinger og farmaceutiske præparater | |
| NO912825L (no) | Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper. | |
| ES2128348T3 (es) | Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular. | |
| SE8800080L (sv) | Laekemedelskomposition | |
| IT1230068B (it) | Procedimento per la preparazione di n sulfoniluree. | |
| DE68907392D1 (de) | Dysmnesie modifizierende arzneimittel. | |
| IT8821300A0 (it) | Procedimento di preparazione di morniflumato e analoghi. | |
| KR900007816A (ko) | 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도 | |
| ATE137487T1 (de) | Komplexe, enthaltend s(+)-phenyl-alkansäuren und alpha-hydroxy-alkansäuren | |
| KR900701299A (ko) | Cpf 펩티드 조성물 및 이를 사용하는 방법 | |
| IT8748235A0 (it) | Peptidi e derivati peptidici, loro preparazione e loro impiego come medicamenti | |
| DK0427633T3 (da) | Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer | |
| NL191736B (nl) | Onverzadigde kamferderivaten en farmaceutische en kosmetische preparaten ervan. | |
| IT9048026A0 (it) | Preparato farmaceutico e/o cosmetico. | |
| FR2631230B1 (fr) | Lit pliable, notamment pour application medicale | |
| FI933386A7 (fi) | Pienimolekyylisiä sulfatoituja poly-b-2,6-fruktofuranosaaneja ja niide n käyttö rappeuttavien nivelsairauksien hoitoon | |
| IT8922175A0 (it) | Derivati amminici di 2,3-diaza-antracene-9,10-dioni come farmaci antitumorali | |
| MX9203129A (es) | Proteinas bmp-5. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |